AdvaMed submitted comments to the Center for Medicare and Medicaid Services (CMS) on its Radiation Oncology (RO) Model proposed rule proposing to indefinitely delay the start date of the RO…
AdvaMed submitted a letter regarding proposed local coverage determinations entitled “Skin Substitutes for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcer.”
AdvaMed urged CDC to recognize the critical role evidence-based and FDA-approved/cleared devices can and should play in improving pain management and reducing opioid-related harms.
During two listening sessions, AdvaMed provided responses to a set of questions posed by CMS on the parameters for a new TCET program, including the types of guidance provided by…
AdvaMed submitted a response to a Department of Health and Human Services (HHS) Office of the National Coordinator for Health Information Technology (ONC) Request for Information (RFI) on electronic prior…
AdvaMed submitted a response to a White House Office of Science and Technology Policy (OSTP) Request for Information (RFI) on Strengthening Community Health Through Technology.
AdvaMed submitted a response to a U.S. House of Representatives Healthy Futures Task Force, Subcommittee on Treatments (Subcommittee on Treatments) Request for Information (RFI) on information to help foster patient…
AdvaMed submitted a letter to the Centers for Medicare and Medicaid Services (CMS) regarding coverage and payment policies for skin substitute products as used and paid for in the outpatient…
In advance of CMS’ release of the proposed End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) rule, AdvaMed submitted a letter focused on coverage and payment policies for ESRD patients.
AdvaMed submitted comments on the Centers for Medicare and Medicaid Services’ Advance Notice of Methodological Changes for Calendar Year 2023 for Medicare Advantage Capitation Rate and Part C and Part…